Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All acetaminophen studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAcetaminophenAcetaminophen (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Liver injury -41% Improvement Relative Risk Acetaminophen  Marín Dueñas et al.  EARLY TREATMENT Is early treatment with acetaminophen beneficial for COVID-19? Retrospective 1,100 patients in Peru Higher progression with acetaminophen (p=0.045) c19early.org Marín Dueñas et al., Annals of Hepatol.., Sep 2021 Favors acetaminophen Favors control

Alteration in liver function tests among patients hospitalized for COVID-19: a multicentric study in Peru

Marín Dueñas et al., Annals of Hepatology, doi:10.1016/j.aohep.2021.100391
Sep 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
1st treatment shown to increase risk in November 2020
 
*, now known with p = 0.00000029 from 28 studies, but still recommended in 44 countries.
* From meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Retrospective 1,100 COVID-19 patients in Peru, showing higher risk of liver injury with paracetamol use. Paracetamol is also known as acetaminophen, Tylenol, Panadol, Calpol, Tempra, Calprofen, Doliprane, Efferalgan, Grippostad C, Dolo, Acamol, Fevadol, Crocin, and Perfalgan.
risk of liver injury, 41.0% higher, OR 1.41, p = 0.045, liver injury, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Marín Dueñas et al., 30 Sep 2021, retrospective, Peru, peer-reviewed, median age 31.5, 10 authors.
This PaperAcetaminophenAll
Abstract: Abstracts P-25 SLOWER FIBROSIS PROGRESSION IN HEPATITIS C HEMOPHILIAC PATIENTS? Dauana O. Bastos, Christini Emori, Sandra V. Antunes, Flavia Appel, Maria Lucia Ferraz ~o Paulo, Sa ~o Paulo, Brazil Universidade Federal de Sa Introduction: The improvement in the treatment of hemophilia from the 900 s, as well as the advent of interferon-free therapy against HCV enabled a better evolution of these special group of patients. However, the impact of hemophilia on the progression of liver fibrosis is still not completely understood. Objectives: To evaluate the progression of liver fibrosis in hemophiliac patients with HCV using non-invasive methods after ten years of follow-up. Casuistic and Method: Retrospective cohort study of hemophiliac patients with HCV evaluated in 2007 and reassessed 10 years later (2017/2018). Hepatic fibrosis was indirectly evaluated by APRI and transient hepatic elastography by Fibroscan Ò - EHT). Results: Sixty-six hemophiliac patients were evaluated in 2007 (all men, median age 31.5 years, 87.9% hemophilia A). Forty-two patients could be reevaluated in 2017/2018. Thirty-three patients were treated with 90.9% SVR; thus, after 10 years, 30 patients were non-viremic and 12 were viremic (3 without SVR and 9 untreated). APRI values were low in both periods but showed a significant reduction in treated patients (0.36 vs 0.20, p <0.001), remaining stable in non-treated (0,61 vs 0,51, p=NS). Fibrosis by EHT was assessed only in 2017/2018 and also showed results compatible with low stages of fibrosis in treated and even in non-treated patients (4.75 and 5.25 kPa, respectively). Conclusions: After ten years of follow-up the results suggest a slower progression and a more benign evolution of hepatic fibrosis among hemophiliacs. Antiviral therapy against HCV showed an elevated response rate, similar to the general population. https://doi.org/10.1016/j.aohep.2021.100389 P-26 PORTAL VENOUS THROMBOSIS IN TRANSPLANTED CIRRHOTIC PATIENTS AT THE “HOSPITAL CLINICO UNIVERSIDAD DE CHILE” V.N. Henríquez Auba1, F. Ramirez1, M. Fabres2, P. Abarca2, B. Astrosa2, D. Vera1, J.C. Diaz3, J. Castillo3, 3, M. Cattaneo1, J. Poniachik1,3, H. Lembach3, A. Saure A. Urzua1,3 n de Gastroenterología, Universidad de Chile, Seccio Santiago, Chile 2 Universidad de Chile, Santiago, Chile 3 Universidad de Chile, Unidad de Trasplantes, Santiago, Chile 1 Background: Portal vein thrombosis (PVT) is a frequent complication in cirrhotic patients on the waiting list for liver transplantation (LT); this is associated with increased post-LT mortality. Objective: Characterize the presence of PVT in patients with LT. Methods: Retrospective observational study between January 1, 2014 and February 28, 2018. Clinical records, laboratory and images were reviewed. Results: 82 patients were included; Age 58 (21-71) years; Etiology: non-alcoholic fatty liver 40.2%, alcoholic liver disease 20.7%, autoimmunity 13.4%, and hepatitis C 8.5%; Child-Pugh: 7.3% A, 30.4% B and 62.2% C; MELD-Na 22 (8-40). PVT was diagnosed before or during LT in 26.8%: Child A 16.6%, B 16.0%, and C 33.3%; MELD-Na 25 (1240) in those with PVT vs 21 (8-40) in those without PVT (non significant, NS); 34% had hepatocarcinoma (32.1% with PVT vs. 24.4% Annals of Hepatology 24 (2021) 100366 without PVT; NS). Diagnosis of PVT was 77.2% pre LT and almost 1/4 during transplant surgery. The extension of the PVT was complete occlusion in 11.7%, partial in 70.5%; 11.7% had only intrahepatic branches compromised..
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit